Development and Clinical Testing of Effective Immunotherapies for Biliary Tract Cancers.

胆道癌有效免疫疗法的开发和临床测试。

• 批准号: 477184
• 负责人: Ilkow Carolina S
• 金额: $ 205.44万
• 依托单位: Ottawa Hospital Research Institute
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-09-01 至 2027-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=477184&lang=en
• 关键词: Biliary Track Cancers; Cancer-Killing Viruses; Cholangiocarcinoma; Hope; Immunoprofiling; Immunotherapy; Multidisciplinary Approach; Nk Therapy; Patient-Centric; Til Therapy

The Challenge: Biliary tract cancers (BTC) are rare (~1,000 new cases in Canada per year). When localized, surgical resection is possible, but most patients present with Stage IV disease, where the estimated 5-year survival is <2%. Current systemic chemot

挑战：胆道癌（BTC）很少见（加拿大每年约有1，000例新病例）。当局部化时， 手术切除是可能的，但大多数患者表现为IV期疾病，估计5年 存活率<2%。当前全身化疗